This e-learning course discusses current and future treatment of unresectable HCC and how to select patients for combination immunotherapy treatment

  • Combination therapy for unresectable or advanced HCC patients, covering both approved therapies and those that are in clinical development.
  • Defining the HCC patient population who should benefit most from each available treatment option based on efficacy and safety profiles.
  • Guidance on treatment sequencing.

This course has been accredited by EACCME® for 1 ECMEC® (as detailed within the Introduction and Objectives below).

This e-learning course discusses treatment sequencing in advanced hepatocellular carcinoma (HCC). Key clinical questions will be addressed, including:

  • What does the current systemic treatment landscape for advanced HCC look like?
  • What is the role of novel systemic therapies and immunotherapy?
  • What is the impact of treatment sequencing?
  • What are the main adverse events associated with targeted therapy and immunotherapy, including immune-related hepatotoxicity?
  • What will be the future role of tissue-based biomarkers in HCC?

The recent SARAH and SIRveNIB trials looked to clarify the impact of SIRT versus sorafenib in patients with locally advanced HCC. What did they show? What are the implications for practice? And what other recent publications can help to shed light on this treatment question? The proceeding e-learning course will take you through our experts’ views on the results from these important studies.

This e-learning course discusses the changing treatment landscape in hepatocellular carcinoma (HCC) and how therapy can be optimised for the individual patient. Key clinical questions will be addressed, including;

  • When and how to transition from loco-regional to systemic therapy?
  • What is the role of novel systemic therapies and immunotherapy?
  • What is the impact of treatment sequencing?

During the e-learning, Experts will present different patient case studies to enhance your understanding of this area.

EACCME Accreditation

COR2ED Checkpoint, made available on and organized by COR2ED, is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists.

Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS). Only those e-learning materials that are displayed on the UEMS-EACCME website have formally been accredited.

Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.

Information on the process to convert EACCME credit to AMA credit can be found at